Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL166701 | 0.75 | MAPT (0.56) | S100A4MAPTKMT2ARECQLMCL1 | |
| SCHEMBL35211484 | 0.75 | MAPT (0.56) | S100A4MAPTKMT2ARECQLMCL1 | |
| SCHEMBL6753541 | 0.74 | PARP1 (0.46) | MAPTKMT2ATDP1ALDH1A1PTPRC | |
| SCHEMBL4573599 | 0.72 | MAPT (0.53) | S100A4MAPTKMT2ARECQLMCL1 | |
| SCHEMBL768880 | 0.72 | MAPT (0.53) | S100A4MAPTKMT2ARECQLMCL1 | |
| SCHEMBL8499259 | 0.72 | MAPT (0.66) | S100A4MAPTKMT2ARECQLMCL1 | |
| SCHEMBL16847064 | 0.71 | MAPT (0.51) | S100A4MAPTKMT2ARECQLMCL1 | |
| SCHEMBL31456583 | 0.71 | MAPT (0.51) | S100A4MAPTKMT2ARECQLMCL1 | |
| SCHEMBL7469716 | 0.70 | TDP1 (0.45) | S100A4MAPTKMT2ARECQLMCL1 | |
| SCHEMBL8519148 | 0.70 | S100A4 (0.55) | S100A4MAPTKMT2ARECQLMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1369412-B1 | Process for the preparation of 5-nitro-3,4-dihydro-1(2H)-naphthalenone, 1,5-naphthalendiamine and 1,5-naphthalendiisocyanate | BAYER MATERIALSCIENCE AG (DE) | 2011-07-27 | — | — | EP | claimed |
| US-6706924-B2 | INCLUDES A STEP IN WHICH ORTHO-NITROTOLUENE IS REACTED WITH ONE OR MORE ACRYLIC ACID DERIVATIVES SUCH AS ACRYLONITRILE | BAYER AKTIENGESELLSCHAFT (DE) | 2004-03-16 | — | — | US | claimed |
| EP-1369412-A1 | Process for the preparation of 5-nitro-3,4-dihydro-1(2H)-naphthalenone, 1,5-naphthalendiamine and 1,5-naphthalendiisocyanate | BAYER AG (DE) | 2003-12-10 | — | — | EP | claimed |
| EP-1345888-A1 | METHOD FOR THE PRODUCTION OF 1,5-NAPHTHALENEDIAMINE | Bayer Aktiengesellschaft (DE) | 2003-09-24 | — | — | EP | claimed |
| US-20020103401-A1 | Process for the production of 1,5-naphthalenediamine | BAYER AKTIENGESELLSCHAFT (DE) | 2002-08-01 | — | — | US | claimed |
| WO-2002051792-A1 | METHOD FOR THE PRODUCTION OF 1,5-NAPHTHALENEDIAMINE | BAYER AKTIENGESELLSCHAFT (DE) | 2002-07-04 | — | — | WO | claimed |
| EP-1369412-B1 | Process for the preparation of 5-nitro-3,4-dihydro-1(2H)-naphthalenone, 1,5-naphthalendiamine and 1,5-naphthalendiisocyanate | BAYER MATERIALSCIENCE AG (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-7202384-B2 | Process for producing 5-nitro-3,4-dihydro-1(2H)-naphthalinone, 1,5-naphthalenediamine and 1,5-naphthalene diisocyanate | BAYER MATERIALSCIENCE AKTIENGESELLSCHAFT (DE) | 2007-04-10 | — | — | US | disclosed |
| US-7202378-B2 | Process for producing 5-nitro-3,4-dihydro-1(H)-naphthalinone, 1,5-naphthalenediamine and 1,5-naphthalene diisocyanate | BAYER MATERIALSCIENCE AG (DE) | 2007-04-10 | — | — | US | disclosed |
| US-20060183946-A1 | Process for producing 5-nitro-3,4-dihydro-1(H)-naphthalinone, 1,5-naphthalenediamine and 1,5-naphthalene diisocyanate | COVESTRO DEUTSCHLAND AG (DE) | 2006-08-17 | — | — | US | disclosed |
| US-20060178526-A1 | Process for producing 5-nitro-3,4-dihydro-1(2H)-naphthalinone, 1,5-naphthalenediamine and 1,5-naphthalene diisocyanate | COVESTRO DEUTSCHLAND AG (DE) | 2006-08-10 | — | — | US | disclosed |
| US-7057071-B2 | Process for producing 5-nitro-3,4-dihydro-1(2H)-naphthalinone, 1-5-naphthalenediamine and 1,5-naphthalene diisocyanate | BAYER MATERIALSCIENCE AG (DE) | 2006-06-06 | — | — | US | disclosed |
| US-6706924-B2 | INCLUDES A STEP IN WHICH ORTHO-NITROTOLUENE IS REACTED WITH ONE OR MORE ACRYLIC ACID DERIVATIVES SUCH AS ACRYLONITRILE | BAYER AKTIENGESELLSCHAFT (DE) | 2004-03-16 | — | — | US | disclosed |
| US-20030229252-A1 | Process for producing 5-nitro-3,4-dihydro-1(2H)-naphthalinone, 1-5-naphthalenediamine and 1,5-naphthalene diisocyanate | COVESTRO DEUTSCHLAND AG (DE) | 2003-12-11 | — | — | US | disclosed |
| EP-1369412-A1 | Process for the preparation of 5-nitro-3,4-dihydro-1(2H)-naphthalenone, 1,5-naphthalendiamine and 1,5-naphthalendiisocyanate | BAYER AG (DE) | 2003-12-10 | — | — | EP | disclosed |
| EP-1345888-A1 | METHOD FOR THE PRODUCTION OF 1,5-NAPHTHALENEDIAMINE | Bayer Aktiengesellschaft (DE) | 2003-09-24 | — | — | EP | disclosed |
| US-20020103401-A1 | Process for the production of 1,5-naphthalenediamine | BAYER AKTIENGESELLSCHAFT (DE) | 2002-08-01 | — | — | US | disclosed |
| WO-2002051792-A1 | METHOD FOR THE PRODUCTION OF 1,5-NAPHTHALENEDIAMINE | BAYER AKTIENGESELLSCHAFT (DE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103401-A1 | Process for the production of 1,5-naphthalenediamine | BBOX1, CYP4B1, NAT1 | S100A4 834/4885MAPT 2586/4885KMT2A 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.